Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

In a report released on October 4, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $140.00. The company’s shares closed ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Bristol Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the treatment of various types of cancer ...

Customers can round up their purchases to the nearest dollar during checkout at the store, and all donations will go to the American Red Cross to help individuals and families affected by the ...

Luke Littler has admitted his World Grand Prix debut "didn't go to plan" after losing in the first round to Rob Cross, who said he did not fear the 17-year-old prodigy. Littler has won nine titles ...

Prime Video has released the official trailer and some first-look images for its upcoming crime thriller series Cross, based on James Patterson’s bestselling Alex Cross book series, starring ...